TrialFrontiers in immunology2024

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4.

Doris K Hansen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.